Cat. No.: HY-15578

McMMAF

(Synonyms: Maleimidocaproyl monomethylauristatin F)

8 Cited Publications

Avis client

Based on 8 publication(s) in Google Scholar

McMMAF (Maleimidocaproyl monomethylauristatin F) is an active molecule linker for ADC, made by coupling the powerful microtubule inhibitor Monomethyl auristatin F (MMAF) (HY-15579) with the protecting group maleimidocaproyl. McMMAF can be conjugated with anti-BCMA antibodies to form J6M0-mcMMAF, promoting apoptosis and inhibiting tumor growth.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.97%
CAS No.: 863971-19-1
Formule: C₄₉H₇₆N₆O₁₁
Masse moléculaire:925.16

Stockage:

-20°C, stored under nitrogen

* The compound is unstable in solutions, freshly prepared is recommended.

McMMAF Chemical Structure

CAS No.: 863971-19-1

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

One-stop CDMO Service

One-Stop Platform：From Independent R&D to Pilot-Scale Production

Activité biologique
- Description
- IC₅₀ & Target
- In Vitro
Chemical Information
Publications (8)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

Auristatin

Voir tous les produits spécifiques à Isoform Drug-Linker Conjugates for ADC :

In Vitro

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 863971-19-1
Appearance Solid
Masse moléculaire 925.16
Formule C₄₉H₇₆N₆O₁₁
Color White to off-white
SMILES

O=C([C@H](C)[C@H]([C@]1([H])CCCN1C(C[C@@H](OC)[C@@]([H])(N(C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(CCCCCN2C(C=CC2=O)=O)=O)=O)=O)C)[C@@H](C)CC)=O)OC)N[C@H](C(O)=O)CC3=CC=CC=C3
Synonyms

Maleimidocaproyl monomethylauristatin F
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

-20°C, stored under nitrogen

* The compound is unstable in solutions, freshly prepared is recommended.

Publications (8)

All

Sort by:

Journal Impact Factor

J Control Release

Optimizing the anti-tumor efficacy of protein-drug conjugates by engineering the molecular size and half-life. [Abstract]

2020 Nov 10:327:186-197. PMID: 32768630
J Pharm Anal

Synergistic approach to combating triple-negative breast cancer: DDR1-targeted antibody-drug conjugate combined with pembrolizumab. [Abstract]

2025 May;15(5):101100. PMID: 40521369
Anal Chem

Site-Specific Conjugation Quantitation of a Cysteine-Conjugated Antibody-Drug Conjugate Using Stable Isotope Labeling Peptide Mapping LC-MS/MS Analysis. [Abstract]

2022 Feb 15;94(6):2772-2778. PMID: 35100801
Pharmaceutics

A Dual-Payload Bispecific ADC Improved Potency and Efficacy over Single-Payload Bispecific ADCs. [Abstract]

2025 Jul 25;17(8):967. PMID: 40870990
Neoplasia

Rational payload selection enables high antitumoral efficacy of an anti-EGFR antibody-drug conjugate against ovarian tumors. [Abstract]

2026 Mar 12:74:101295. PMID: 41825107
Patent

US20210393733A1.
Patent

US10087260B2.
Patent

US20160304621A1.

Solvant et solubilité

In Vitro:

DMSO : ≥ 100 mg/mL (108.09 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.0809 mL

5.4045 mL

10.8089 mL

5 mM

0.2162 mL

1.0809 mL

2.1618 mL

10 mM

0.1081 mL

0.5404 mL

1.0809 mL

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (5.40 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (5.40 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 3

Add each solvent one by one: 1% DMSO 99% Saline

Solubility: ≥ 0.5 mg/mL (0.54 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (275 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Polson AG, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res. 2009 Mar 15;69(6):2358-2364. [Content Brief]

[2]. Jianmin Fang, et al. Anti-her2 antibody and conjugate thereof. US 20160304621 A1.

[3]. Yu-Tzu Tai, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014 May 15;123(20):3128-38. [Content Brief]

[4]. Katja Weisel, et al. Dreamm-3: A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin (GSK2857916) Monotherapy Compared with Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 13 November 2019, Page 1900.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.0809 mL	5.4045 mL	10.8089 mL	27.0224 mL
	5 mM	0.2162 mL	1.0809 mL	2.1618 mL	5.4045 mL
	10 mM	0.1081 mL	0.5404 mL	1.0809 mL	2.7022 mL
	15 mM	0.0721 mL	0.3603 mL	0.7206 mL	1.8015 mL
	20 mM	0.0540 mL	0.2702 mL	0.5404 mL	1.3511 mL
	25 mM	0.0432 mL	0.2162 mL	0.4324 mL	1.0809 mL
	30 mM	0.0360 mL	0.1801 mL	0.3603 mL	0.9007 mL
	40 mM	0.0270 mL	0.1351 mL	0.2702 mL	0.6756 mL
	50 mM	0.0216 mL	0.1081 mL	0.2162 mL	0.5404 mL
	60 mM	0.0180 mL	0.0901 mL	0.1801 mL	0.4504 mL
	80 mM	0.0135 mL	0.0676 mL	0.1351 mL	0.3378 mL
	100 mM	0.0108 mL	0.0540 mL	0.1081 mL	0.2702 mL

Keywords

McMMAF

8 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

McMMAF

Publications Citing Use of MedChemExpress (MCE) McMMAF

Voir tous les produits spécifiques à Isoform Drug-Linker Conjugates for ADC

Activité biologique

Chemical Information

Publications (8)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

McMMAF Related Classifications

HY-15578 Related Classifications